

Results of cooperation of the EBA Health Care Committee

On 09.10.2007 the EBA Health Care Committee – would like to inform about the results of cooperation with the responsible for the pharmaceutical products expertise and marketing access state authorities of Ukraine.

The EBA Health Care Committee (herewith – Committee) as the representative of the international pharmaceutical industry – the source of innovations into the sector, supports steps to the harmonisation of the pharmaceutical products expertise and marketing access system in Ukraine with the EU standard. Systematical actions allow us to guarantee the high quality and safety pharmaceutical products for Ukrainian consumers in the nearest future.

We think that changes of the existing system of expertise, access and control of the pharmaceutical products circulation in Ukrainian market should be implemented by the Ukrainian Government only after the the preparation of the concept of such changes as well as the wide public discussions with all interested parties, including the pharmaceutical industry. The issues of the industry management system should be considered in the framework of the current legislation of Ukraine, particularly Laws of Ukraine, namely: On Fundamentals of States Supervisions (Control) of Economic Activity, On Fundamentals of State Regulatory Policy in Field of Economic Activity, On the Cabinet of the Ministries of Ukraine, On Medical Drugs.

The public and constructive position of the State Pharmacology Center of Ukraine, the State Service on Medical Drugs and Medical Devices of Ukraine and the State Inspection on Medical Drugs Quality Control in cooperation with pharmaceutical manufacturers both global and local, resulted in open and transparent relations among the industry, allowed to get rid of some abuses and subjectivism.

The participation of mentioned above relevant health care state authorities in the high level events, namely: Annual EU-Ukraine Summit in Helsinki (November 2006), EU – Ukraine negotiation on the Intellectual Property Rights issues permits to solve the sectoral problems and guarantee the safety and effectiveness of the medical usage. At the same time the collaboration with the regulatory bodies of the CIS countries let change the situation with the of medical drugs anit-counterfeit actions significantly, that is the regional, problem of the CIS countries.

From our side we guarantee necessary and effective steps to retain the transparency, balance and professionalism in this system.